Sign In
Buy LLY
$1,185.71
-6.23 (-0.523%)
At Close: Aug 07, 2026
Fmr. FDA Commissioner Dr. Scott Gottlieb on diabetes drugs: Overall it's being used appropriately
11:09am, Wednesday, 09'th Aug 2023
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the growing interest in new diabetes drugs, with some showing promise for weight loss and heart disease prevention, the promise
I get stories every day from patients about how Mounjaro is benefiting their lives: Eli Lilly CEO
10:49am, Wednesday, 09'th Aug 2023
Eli Lilly CEO David Ricks joins 'Mad Money' host Jim Cramer to talk the recent stock pop, Eli Lilly weight-loss drug and more.
Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?
08:00am, Wednesday, 09'th Aug 2023
Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer's drugs. But is LLY stock a buy now?
Eli Lilly's stock jumps on promising weight-loss drug
09:04pm, Tuesday, 08'th Aug 2023
Dr. Ezekiel Emanuel, fmr. Obama White House health policy advisor, joins 'Last Call' to talk the Eli Lilly's stock reaction to its weight-loss drug, rising obesity rates in the U.S. and more.
S&P Gains and Losses Today: Bank Stocks Tumble on Moody's Downgrade
05:30pm, Tuesday, 08'th Aug 2023
The S&P 500 dipped 0.4% on Tuesday, Aug. 8, 2023, as bank stocks lost ground after Moody's downgrades.
Eli Lilly beats on Q2 revenue and profit driven by 'a collection' of name brand drug sales: Analyst
04:37pm, Tuesday, 08'th Aug 2023
Pharma giant Eli Lilly's (LLY) stock is soaring after reporting a second-quarter earnings beat, boasting revenue of $8.31 billion and earnings of $2.11 per share. Raising its full-year guidance, the p
Wells Fargo's Mohit Bansal sees durable growth behind Eli Lilly's blockbuster products
03:55pm, Tuesday, 08'th Aug 2023
Mohit Bansal, Wells Fargo equity analyst, joins 'Power Lunch' to discuss Eli Lilly quarterly results as shares soar on Q2 earnings and revenue beats.
3 Stocks to Buy Following Beat-and-Raise Quarters
03:55pm, Tuesday, 08'th Aug 2023
The bulk of the Q2 earnings season is in the rearview mirror, with most S&P 500 companies already unveiling their quarterly results. The period has largely been better than feared, helping to inject s
Eli Lilly (LLY) Stock Just Reached a New All-Time High
02:16pm, Tuesday, 08'th Aug 2023
Pharmaceutical giant Eli Lilly (NYSE: LLY ) delighted investors with an impressive earnings performance, sending LLY stock to a new all-time high. In particular, the company's diabetes treatment Mounj
Weight-Loss Drug Frenzy Drives Eli Lilly And Novo Nordisk Stock To Record Highs
01:51pm, Tuesday, 08'th Aug 2023
Shares of Eli Lilly and Novo Nordisk both soared to record highs on Tuesday, as sales increased of Eli Lilly's Mounjaro and as Novo Nordisk reports a promising clinical trial of its drug Wegovy.
Eli Lilly (LLY) Q2 Earnings Beat, Mounjaro Powers Sales Growth
01:40pm, Tuesday, 08'th Aug 2023
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its financial guidance for 2023.
Markets Plunge at Midday After Bank Downgrades
01:25pm, Tuesday, 08'th Aug 2023
U.S. equities sank at midday on Tuesday, Aug. 8, 2023, following bank downgrades by Moody's and data showing credit card debt rose to a record.
Eli Lilly Beats Estimates and Boosts Its Guidance as Diabetes Drug Sales Soar
12:40pm, Tuesday, 08'th Aug 2023
Eli Lilly shares rose to a record after the company posted better-than-expected results and raised its guidance on soaring demand soared for its diabetes drug, Mounjaro.
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
12:10pm, Tuesday, 08'th Aug 2023
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wa
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Are On Fire Today
11:45am, Tuesday, 08'th Aug 2023
Novo Nordisk's popular weight loss drug significantly reduced the risk of heart attack or stroke in a late-stage trial. These data bode well for the obesity drug category at large.
